Edwards Lifesciences (EW) Receivables - Net (2009 - 2026)

Edwards Lifesciences has reported Receivables - Net for 18 years, with the latest figure at $775.7 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Net rose 15.91% year-over-year to $775.7 million; the trailing twelve-month figure through Mar 2026 stood at $775.7 million (up 15.91% YoY), and the FY2025 full-year result was $659.6 million, up 2190.28% from the prior year.
• Receivables - Net for Q1 2026 stood at $775.7 million, up from $659.6 million in the prior quarter.
• The five-year high for Receivables - Net was $817.6 million in Q1 2024, with the low at $24.6 million in Q3 2024.
• Average Receivables - Net over 5 years is $627.1 million, with a median of $693.3 million recorded in 2025.
• Year-over-year, Receivables - Net tumbled 96.67% in 2024 and soared 2718.29% in 2025.
• Tracing EW's Receivables - Net over 5 years: stood at $643.0 million in 2022, then grew by 19.98% to $771.5 million in 2023, then plunged by 96.27% to $28.8 million in 2024, then surged by 2190.28% to $659.6 million in 2025, then grew by 17.6% to $775.7 million in 2026.
• The last three Receivables - Net figures came in at $775.7 million (Q1 2026), $659.6 million (Q4 2025), and $693.3 million (Q3 2025), per Business Quant data.

Peer Comparison